Study to investigate pharmacokinetics of a single i.v. dose of tiotropium (4.8 mcg) in patients with renal impairment in comparison to healthy subjects.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Area under the curve (AUC (0-4h) of plasma levels of tiotropium after dosing)
Time frame: pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
Renal clearance of tiotropium (CLren )
Time frame: Day 1, 2, 3, 7, 11, 15, 18, 22 and 25 (0-4h, 4-8h), additionally -4 -0 h on day 1
Terminal half-life of tiotropium
Time frame: pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
Urinary excretion (0-4h) of tiotropium, Ae 0-4h
Time frame: Day 1, 2, 3, 7, 11, 15, 18, 22 and 25 (0-4h, 4-8h), additionally -4 -0 h on day 1
Change from baseline in Pulse Rate (PR)
Time frame: baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
Change from baseline in Blood pressure (BP)
Time frame: baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
Number of Participants with Serious and Non-Serious Adverse Events
Time frame: up to day 25
Change from baseline in electrocardiogram (ECG)
Time frame: baseline, day 1, 2, 7, 15 and 25
Maximum measured concentration of the analyte in plasma (Cmax )
Time frame: pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
Time from dosing to the maximum concentration of the analyte in plasma (tmax)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
Change in FEV1 (Forced expiratory volume in one second)
Time frame: baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
Change in FVC (Forced vital capacity)
Time frame: baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25